stock setter

stock news | analysis | analyst ratings|targets

[stock setter @MarcJacksonLA]

$CIFR
-Bernstein initiates Cipher Mining coverage at Outperform
$32 target
-
$CMG
-Morgan Stanley lowers Chipotle Mexican Grill target to $37 from $49
Downgrades to = Weight from Overweight
-
$COPA
-JPMorgan raises Copa target to $170 from $165
Overweight
-

[stock setter @MarcJacksonLA]

$WOOF
Petco posts Q1 2026 results, lifts margins and keeps 2026 outlook

- Petco shows slight top-line growth, better margins, but remains loss-making.

- Petco delivered Q1 2026 net sales of $1.50 billion, up 0.2% with comparable sales up 0.7%.

- Mix and cost actions lifted gross margin to 38.4%, and operating income rose to $24.6 million, supporting Adjusted EBITDA of $97.3 million.

- Despite these improvements, the company reported a net loss of $15.1 million and Free Cash Flow outflow of $69.1 million.

- Net debt stood at $1.32 billion, with total debt of $1.48 billion and cash of $166.8 million, underscoring a still-levered balance sheet.

- Management reaffirmed full-year 2026 guidance for flat to 1.5% net sales growth and Adjusted EBITDA of $415–$430 million, and expects Q2 2026 net sales up about 0.3% with Adjusted EBITDA of $110–$112 million.

- Tariff refunds and fuel costs are cited as key near-term factors for Q2.
https://t.co/h6MttYGxV2

[stock setter @MarcJacksonLA]

$DSGX
Descartes Announces Fiscal 2027 First Quarter Financial Results

- Descartes reported record Q1 FY27 results with revenue of $193.6M, up 15% year-over-year, and gross margin of 78%.

- Net income was $48.5M (25% margin) and diluted EPS $0.55.

- Operating cash flow reached $75.1M and cash rose to $377.0M.

- Adjusted EBITDA was $89.8M (46% margin).

- Descartes repurchased 305,000 shares for $20.8M under its NCIB and completed the Idelic acquisition for $25.3M plus up to $12.0M in contingent consideration.
https://t.co/DOUIaRZxvC

[stock setter @MarcJacksonLA]

$FIVE
Five Below tops first-quarter estimates for revenue and profit

- Net sales increased 32.5% in the quarter to May 2 and comps were up 22.7% from a year earlier.

https://t.co/pzMYv3NmNo

[stock setter @MarcJacksonLA]

$PVH
PVH Exceeds Q1 CY2026 Expectations But Stock Drops 19.7%

- The fashion conglomerate PVH beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 2.1% year on year to $2.03 billion.

- Its non-GAAP profit of $2.01 per share was 10.5% above analysts’ consensus estimates.
https://t.co/0YLCdrOPr2 via @Barchart

[stock setter @MarcJacksonLA]

$VEEV
Veeva Systems Posts Better-Than-Expected Sales In Q1 CY2026

The life sciences cloud software provider reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 16.3% year on year to $882.9 million

https://t.co/2juwyuABmY via @Barchart

[stock setter @MarcJacksonLA]

$CHPT
ChargePoint’s Q1 CY2026: Strong Sales

- The EV charging solutions provider reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 4.3% year on year to $101.8 million.
https://t.co/nhrBw8Wfvv via @Barchart

[stock setter @MarcJacksonLA]

$AI
https://t.co/vUHWJQJM1b Posts Better-Than-Expected Sales In Q1 CY2026, Stock Jumps 11%

- https://t.co/vUHWJQJM1b beat Wall Street’s revenue expectations in Q1 CY2026, but sales fell by 52.5% year on year to $51.6 million.
https://t.co/8wawBFV32l via @Barchart

[stock setter @MarcJacksonLA]

$VEEV
Veeva Systems beats estimates on AI progress

- Revenue reached $882.9 million, surpassing the $857.75 million estimate and marking a 16% increase from $759.0 million in the same quarter last year.
https://t.co/edCjbVocNg

[stock setter @MarcJacksonLA]

$CRWD
CrowdStrike narrowly beats estimates on AI tailwinds, but stock falls 9%

- CrowdStrike announced a four-for-one stock split and narrowly beat Wall Street’s fiscal 2027 first-quarter estimates.

- Shares are up about 60% this year as companies lean into more cyber tools to fend off advanced AI attacks.

- CEO George Kurtz said the company is “critical to successful AI adoption.”

https://t.co/W2RxW48Uk1

[stock setter @MarcJacksonLA]

$AVGO
Broadcom stock slips on disappointing software revenue

- Broadcom reported weaker-than-expected revenue in its fiscal second-quarter earnings report on Wednesday.

- Leading up to the report, revenue has surged in recent quarters, driven by demand for custom AI chips.

https://t.co/Xhk4Yf6CBi

[stock setter @MarcJacksonLA]

$VSTM
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

- Phase 1 TARGET-D 101 dose escalation, dose expansion, and combination clinical trial ongoing with early data updates expected in the first half of 2026 and more mature data expected in the second half of 2026

- Phase 2 registration directed, open label TARGET-D 202 clinical trial initiated for 2L/3L advanced non-small cell lung cancer (NSCLC)

- FDA Fast Track Designation previously granted for VS-7375 for KRAS G12D-mutated advanced or metastatic pancreatic cancer
https://t.co/DldiHbafkb

[stock setter @MarcJacksonLA]

$ELVN
Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress

-Enliven will host a webcast conference call on June 11, 2026 at 8:30 a.m. ET to discuss updated Phase 1 ENABLE clinical trial data for ELVN-001 in previously treated chronic myeloid leukemia, following an oral presentation at the EHA 2026 Congress.
https://t.co/sLKGtqk0Jt

[stock setter @MarcJacksonLA]

$ADCT
ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

- The combo met the primary endpoint, improving progression-free survival (HR=0.73; p=0.008) vs R-GemOx, with higher response and complete response rates and longer complete response duration.

- Overall survival showed no detrimental effect (HR=0.96).

- Total adverse event rates were similar between arms, but serious, Grade 5 events and withdrawals were more frequent with ZYNLONTA + rituximab, especially in patients ≥75.

- ADC Therapeutics plans a pre-sBLA FDA meeting in August and targets an sBLA filing in Q4 2026.
https://t.co/Qcsp5Q14Bp

[stock setter @MarcJacksonLA]

$IOVA
Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

- Iovance received conditional approval from Australia’s Therapeutic Goods Administration for Amtagvi (lifileucel) to treat adults with unresectable or metastatic melanoma after prior PD-1 and, if BRAF V600 positive, targeted therapy.

- This is Amtagvi’s third marketing authorization and the first T cell therapy for a solid tumor cancer in Australia.
https://t.co/ZLQA10QaCb

[stock setter @MarcJacksonLA]

$PENG
Penguin Solutions Recognized as Dell Technologies Global Alliances Americas AI Partner of the Year

- Award highlights Penguin’s expertise in delivering Full-Stack AI Factory Platforms that address the growing demand for optimized large-scale inference and agentic AI workloads
https://t.co/VIEXcH5bC0

[stock setter @MarcJacksonLA]

$NTSK
Netskope Announces Fiscal First Quarter 2027 Financial Results

Netskope reported Q1 fiscal 2027 results, with ARR up 29% year-over-year to $845 million and revenue up 28% to $201.6 million.

- GAAP and non-GAAP gross margins rose to 74% and 77% respectively.

- GAAP operating loss widened to $108.7 million, while non-GAAP operating margin improved to (14%).

- Free cash flow turned negative at ($57.2) million, but cash and investments totaled $1.1 billion.

-Issued fiscal 2027 revenue guidance of $879–$883 million, implying 24%–25% growth, and expects free cash flow margin of 2%–4%.

- Announced major AI product launches, an expanded Deloitte partnership, and a planned CFO retirement with a structured succession process.
https://t.co/1mX8uRGlA4

[stock setter @MarcJacksonLA]

$HUBC
HUB Announces 1-for-20 Reverse Share Split

- The split becomes effective at 11:59 p.m. ET on June 5, 2026, with HUBC starting split-adjusted trading on Nasdaq on June 8, 2026.

- Every 20 existing shares will convert into one share, with no fractional shares issued and amounts rounded down.

- Outstanding shares will change from 66,603,152 to approximately 3,330,157.

- Derivative securities, including options and warrants, will be proportionally adjusted.

- The company believes this action will help support compliance with Nasdaq’s minimum bid price rule.

https://t.co/APlOCFOtU6

[stock setter @MarcJacksonLA]

$AVGO
Broadcom Announces Second Quarter Fiscal Year 2026 Financial Results and Quarterly Dividend

- Broadcom reported revenue of $22.2 billion, up 48% year over year, with GAAP net income of $9.3 billion and GAAP diluted EPS of $1.91.

- Non-GAAP net income was $12.1 billion and non-GAAP EPS $2.44.

- Adjusted EBITDA reached $15.2 billion (69% of revenue).

- Free cash flow was $10.3 billion, 46% of revenue.

- AI semiconductor revenue was $10.8 billion, up 143% year over year.

- For Q3 FY26, Broadcom guides revenue of about $29.4 billion, up 84%, with non-GAAP operating margin of 67% and Adjusted EBITDA at 68% of revenue.

The board declared a quarterly dividend of $0.65 per share, payable June 30, 2026, to shareholders of record on June 22, 2026.
https://t.co/fDVFUt1PBf

[stock setter @MarcJacksonLA]

$CF
-JPMorgan raises CF Industries target to $115 from $94
Neutral
-
$CHWY
-Mizuho lowers Chewy target to $40 from $50
Outperform
-
$CI
-Piper Sandler lowers Cigna target to $346 from $370
Overweight
-
$CIFR
-Morgan Stanley raises Cipher Mining target to $53.50 from $42.50
Overweight
-